head and neck cancer

Researchers have already dosed the first patient with TG4050 and expect to give the immunotherapy to up to 30 more patients in the Phase I study.

The researchers identified molecular subtypes of head and neck cancer that could be susceptible to CDK inhibitor, anti-EGFR antibody, or immunotherapy treatments.

The test will identify patients with squamous cell head and neck cancer caused by specific HPV infections for treatment with BioNTech's investigational BNT113.

In the wake of encouraging interim results, Moderna plans to expand the head and neck cancer cohort of its mRNA-4157 plus Keytruda clinical trial.

The agency made the recommendation based on data showing that Keytruda improved outcomes and was cost-effective compared to the standard treatment.

The partners will integrate CCPM's research biobank with personalized genomic information to develop and commercialize the saliva-based tests.

The firm will conduct genomic and transcriptomic analysis to identify predictors of response to the personalized immunotherapy TG4050.

The company will work with university researchers to evaluate its predictive immune modeling technology in personalizing the use of immune checkpoint inhibitors.